Key Finding
Pharmaceutical and health product companies spent a record $387.47 million on lobbying in 2024 — the highest of any industry, ever. PhRMA alone spent $31.72 million. The industry is on pace for another record in 2025.
The Record
The pharmaceutical industry's 2024 lobbying tab of $387.47 million shattered the previous all-time record set during the Affordable Care Act debates in 2009-2010, when the industry spent approximately $275 million to shape the landmark healthcare law. The numbers come from OpenSecrets analysis of Senate Lobbying Disclosure Act filings.
The Biggest Spender
PhRMA — the Pharmaceutical Research and Manufacturers of America, the industry's primary trade group — spent $31.72 million in 2024, making it the single largest lobbying spender within the healthcare sector. PhRMA employs dozens of lobbyists and retains over 30 external lobbying firms.
What They're Fighting
The spending surge is directly tied to legislative threats to pharmaceutical profits:
- Medicare drug price negotiation: The Inflation Reduction Act authorized Medicare to negotiate prices on select drugs. The industry is fighting to limit the program's expansion.
- Orphan drug provisions: Proposals to reform lucrative orphan drug exclusivity rules
- OBBA legislation: The One Big Beautiful Bill Act includes healthcare provisions the industry is aggressively lobbying on
- PBM reform: Pharmacy benefit manager regulation that could reshape drug pricing
The Trump Connection
In a notable development, pharma companies have been boosting spending on Trump-connected lobbying firms, according to STAT News (February 2026). Companies are hiring firms with close ties to the administration, betting that personal connections will be more effective than traditional lobbying.
Pharma Lobbying: Historical Record
| Year | Lobbying Spend | Context |
|---|---|---|
| 2009 | $275M | ACA debates |
| 2018 | $283M | Drug pricing push |
| 2022 | $356M | IRA negotiations |
| 2024 | $387M | ALL-TIME RECORD |
The Revolving Door
The pharma lobbying machine is fueled by a massive revolving door. Former members of Congress, congressional staffers, and FDA officials regularly move to pharmaceutical companies and lobbying firms. This pipeline ensures that industry lobbyists have personal relationships with the very officials they're lobbying — and intimate knowledge of how to navigate the legislative process.
Does It Work?
The evidence suggests the spending is highly effective. Despite overwhelming public support for drug price negotiation (80%+ in polls), the Inflation Reduction Act's negotiation provisions were severely limited — covering only 10 drugs in its first year. Broader drug pricing reforms have repeatedly stalled in Congress, killed by industry opposition.
The Bottom Line
The pharmaceutical industry spends more on lobbying than any other sector in America. At $387 million in 2024, it outspends the defense, oil, and tech industries combined. The investment has successfully delayed, weakened, or killed virtually every major drug pricing reform effort of the past two decades.
Sources
- OpenSecrets: Pharmaceutical/health products lobbying reports (2024)
- Investopedia: "Pharma lobbying hits all-time record" (2024)
- STAT News: "Pharma companies boost Trump-connected lobbying" (February 2026)
- Senate Lobbying Disclosure Act filings
- Kaiser Family Foundation: Public opinion polling on drug pricing